Find out what's happening on campus and across the industry.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
The company’s off-the-shelf or ‘allogeneic’ therapy tabelecleucel – now given the Ebvallo trade name – has been approved by the European Commission as a second-line treatment for a rare and potentially deadly cancer that afflicts some organ or bone marrow transplant recipients.
The University of Colorado Anschutz Medical Campus has been named one of the top academic institutions in the world for innovation, according to Nature’s 2022 Innovation Index report. The report ranked CU Anschutz in the top four universities globally for forging the strongest innovations links.
Colorado BioScience Association today announced annual fundraising totals for the state’s life sciences ecosystem. Companies, organizations, and researchers in the state’s life sciences community raised $1.6 billion in 2022, marking the sixth year fundraising totals hit more than $1 billion. The numbers are consistent with life sciences funding trends across the U.S., with activity remaining strong but returning to pre-pandemic levels following a record-breaking 2021.
Bringing together industry partners, entrepreneurs, and investors to help CU researchers and healthcare practitioners solve important medical problems and improve the quality of life for patients worldwide. We strive to enable healthcare advancements and scientific research that will benefit society, while also generating a sustainable revenue stream for the University.
Osage University Partners Interviews Melissa Krebs, CEO and Founder of GelSana and Associate Professor at Colorado School of Mines.
A conversation with Melissa Krebs, CEO and Founder of GelSana and Associate Professor at Colorado School of Mines.
The award recognizes the investments Fitzsimons Innovation Community is making to advance Colorado’s life sciences community and better position the entire ecosystem for growth
Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials
Congresswoman Diana DeGette (D-CO) visits the Gates Biomanufacturing Facility's Protein Suite, in which GMP-grade AV-1980R was manufactured for the Institute for Molecular Medicine's phase 1 clinical...
Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.
Rather than just redirecting flow, implantations provide therapy to heart cells and drive new tissue
Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers
Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).